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distinguished: monogenic disorders, i. e. diseases caused 
by a single gene (e. g. Duchenne muscular dystrophy), 
and aneuploidies or translocations, i. e. changes in the 
number or arrangement of chromosomes.
The challenge for society is to define the legitimate use of 
this method of reproductive medicine, adequately taking 
into account the different interests affected by PGD. On 
the one hand, PGD as a method of selecting embryos is al-
most inevitably associated with discarding embryos. It also 
requires IVF to be carried out with all its burdens on the 
woman, even in cases where a couple would be able to con-
ceive children naturally. In addition, there are fears that the 
decision to consider certain diseases to be unacceptable will 
also result in a derogatory judgement of those affected by 
such diseases and thus discriminate against them. On the 
other hand, affected couples have the desire to have a genet-
ically related child who is not affected by a serious genetic 
disease or chromosomal disorder. Very often, couples seek-
ing PGD have experienced multiple miscarriages or have 
children affected by a disease. By many people, a »trial« 
pregnancy with prenatal diagnosis (PND) and possible late 
termination is considered to be more problematic than 
making use of PGD.
Regulation in Germany and Europe
For the first time, PGD was carried out successfully in Eng-
land in 1990. In Germany, an explicit legal regulation was 
agreed upon comparatively late. Until 2010, PGD was con-
sidered to be prohibited by the former Embryo Protection 
Act. However, the German Federal Court of Justice ruled 
that certain forms of PGD complied with the law and called 
for a distinct legal regulation. In 2011, after extensive parlia-
Summary
 › Pre-implantation genetic diagnosis enables the genetic 
testing of embryos in the process of in vitro fertilisation 
before they are transplanted.
 › The method raises ethical questions, affects different 
societal interests and therefore represents a continuing 
legislative challenge.
 › In 2011, balancing individual and societal interests with 
regard to the handling of embryos and discrimination 
against those affected, a majority of the German Bun-
destag voted for a strictly limited authorisation.
 › To date, with around 300 applications per year, the 
number of people making use of PGD corresponds to 
the estimations formulated in the legislative process. 
The further development depends on questions regard-
ing reimbursement, the number of indications approved 
by the PGD Ethics Committees and the clarification of 
open legal questions.
What is involved
Pre-implantation genetic diagnosis (PGD) is the genetic 
testing of embryos produced by means of in vitro fertili-
sation (IVF). For PGD, several embryos are produced and 
tested with regard to genetic traits that could lead to serious 
diseases, disabilities or even death of the embryo or child. 
Only embryos that do not have disease-related characteris-
tics are used to establish a pregnancy.
In Germany, PGD is generally prohibited, but permitted 
under certain conditions. In § 3a of the Embryo Protection 
Act, the following conditions for an exemption of punish-
ment are specified:
 › the high risk of a serious hereditary disease or
 › serious damage to the embryo, which is most likely to 
lead to stillbirth or miscarriage.
 › There is no list of indications, since – according to the 
law – each individual case is to be considered with all 
its particularities. However, two groups of cases can be 
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but only few scientifically founded evaluations are availa-
ble. The compilation of available data from various sourc-
es (PGD Ethics Committees, publications, media reports) 
shows an increase in the number of PGD applications over 
the past few years, but also a total number of approvals 
that is in line with the expected few hundred treatments. 
In 2018, according to a media report, slightly more than 
300 applications for PGD were submitted, of which approx-
imately 90 % were approved.
Three groups of stakeholders, each with an own perspective, 
are essentially involved in the implementation of PGD: the 
couples, the PGD centres and the PGD Ethics Committees. 
Couples are usually interested in PGD as a result of their 
personal history, for example because they have been diag-
nosed with a genetic disease or because they have had several 
stillbirths or miscarriages. They receive information in the 
course of a human genetic counselling, in a fertility centre, 
through self-help organisations of affected persons or (in 
varying quality) via the Internet. Afterwards, they can find 
contact persons and advice in one of the eleven PGD centres.
mentary and public debates, the German Bundestag added a 
new § 3a to the Embryo Protection Act. In addition to limit-
ing the use of PGD to the indications mentioned above, this 
new article provides for institutional regulations (particu-
larly regarding the competence of an Ethics Committee) as 
well as strict quality requirements (i. a. implementation only 
by officially approved PGD centres). In 2014, the associated 
»Order on the Lawful Conduct of Pre-implantation Genetic 
Diagnosis« (German: »Verordnung zur Regelung der Präim-
plantationsdiagnostik« [PIDV]) came into force and corre-
sponding regulations at the Länder level followed. Only on 
this basis, the PGD centres and Ethics Committees were able 
to start their work.
The purpose of the amendment was to create the basis for a 
strictly limited implementation of PGD in Germany. In this 
context, a central role is played by the PGD Ethics Com-
mittees, which have to check for each application for PGD 
whether the conditions for impunity are met. In the mean-
time, legal action has been taken against negative decisions 
made by committees. In one case (not yet final), it was 
decided that the decisions can only be reviewed in court 
to a limited extent, but that the actual assessment (in this 
case whether the expected disease is »serious« as defined 
by law) cannot be made by a court. Another issue under 
judicial review is whether trophectoderm biopsy – current-
ly the standard procedure for PGD, for which only cells of 
the outer cell layer of the embryo are removed – requires 
the approval of a PGD Ethics Committee. Moreover, the 
German Federal Social Court determined that the costs of 
a PGD are not cov ered by the statutory health insurance 
scheme.
Within Europe, PGD is legally possible in all EU countries, 
even if explicit legal regulations do not exist in all countries. 
A possible use of PGD for sex selection without medical in-
dication is prohibited throughout the EU. Apart from that, 
there are sometimes considerable differences with regard to 
the spectrum of admissible indications and the institutional 
implementation – with regulation in Germany being one of 
the more restrictive ones. Several countries have set up spe-
cific authorities to control PGD practice. These authorities 
are responsible for approving PGD centres and for determin-
ing admissible indications (e. g. the largely independent UK 
Human Fertilisation and Embryology Authority). In some 
countries, it is only up to the couples to decide. In other 
countries, however, counselling (Switzerland) or approval 
(France) by medical experts is mandatory.
Practical implementation of PGD in Germany
In the discussion on legal regulation, the expected effects of 
the law as well as the issue of limiting the use of PGD were 
discussed again and again. Meanwhile, first experiences, 
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Fig. 1  Steps towards PGD
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clinics also offer their services specifically in German. In 
turn, couples from abroad use the services of German PGD 
centres.
The PGD centres each consist of a human genetic centre and 
one or more fertility centres. These do not necessarily have 
to be located at the same site. The centres exchange infor-
mation on procedures and experiences at the technical level 
and work according to common guidelines, but in principle 
independently of each other. Their respective capacity to car-
ry out examinations depends on the financial and technical 
resources as well as on the experience of the staff. A PGD 
centre can refuse treatment if there is not sufficient capacity 
or if the chances of success are considered to be too low from 
a medical perspective or in view of the Ethics Committee’s 
decision.
With eight members each, the PGD Ethics Committees are 
interdisciplinary and represent four different medical disci-
plines, ethics and law as well as organisations of patients and 
people with disabilities. They are supported by branch offices 
and charge fees for the processing of applications (EUR 300 
to 3,000, depending on the effort involved and the support-
ing institution), whereas their members work on a voluntary 
basis. In Germany, there are five committees, two of which 
are responsible for several Länder. Each case is assessed in-
dividually by the members of the committees. For this, they 
mainly focus on the medical indication. In ambiguous cases, 
however, the personal circumstances are also taken into con-
sideration. Thus, it may happen that applications are assessed 
differently by the same committee, though they are appar-
ently based on the same indication. Nevertheless, in order 
to create a common framework for decisions, the committee 
members have intensive discussions with each other as well 
as with the members of other PGD Ethics Committees. For 
an application to be approved, two thirds of the members 
must agree.
Current lines of development
Further development will be influenced in particular by the 
legal framework and its interpretation by courts, PGD Ethics 
Committees and PGD centres. Other influencing factors are 
framework conditions such as the regulation of reimburse-
ment and admissible indications as well as the development 
of medical research and technology.
The legal regulation of PGD is meant to balance individual 
and societal interests in particular with regard to the handling 
of embryos and discrimination against those affected. Fun-
damental questions such as the regulation of PGD by means 
of a specific act on reproductive medicine instead of the cur-
rent criminal law provisions given in the Embryo Protection 
Law or the different legal treatment of PGD and PND are 
In the course of the multi-stage counselling and deci-
sion-making process, some of the initially interested couples 
(between 50 and 88 %, depending on the survey used) refrain 
from submitting an application to a PGD Ethics Committee. 
For this, the following factors might play a role:
 › the intensity of the couple’s desire to have children and 
their attitude to late termination – for some couples, 
pregnancy with PND is an alternative to PGD, especially 
as an additional PND is also recommended for PGD;
 › the costs of PGD, which are not assumed by health insur-
ance companies (a total of approx. EUR 15,000 to 20,000);
 › the uncertainty of success in view of the effort involved 
(potentially with several treatment cycles) and the risks 
of the treatment, especially for the woman;
 › the examination procedure of the respective PGD Ethics 
Committee, which is perceived as an obstacle.
For some couples, going abroad is an alternative, because 
access to treatment abroad is easier or geographically near-
by, or because more options are available. Corresponding 
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Fig. 2  Stages of PGD
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a resulting list of indications. In addition, there is a need for 
research with regard to studies on couples interest in PGD, 
on the quality of available information and counselling as 
well as on experience made with PGD. Moreover, the discus-
sion about aneuploidy screenings illustrates that studies on 
medical quality criteria of PGD and associated IVF proce-
dures represent a desideratum.
The existing legal provision allows PGD to be carried out 
while, at the same time, strictly limiting its application. The 
situation could change if courts would reinterpret the Embryo 
Protection Act. Furthermore, a legislative initiative would be 
required to amend the reimbursement scheme. It seems to 
be recommendable to continue observing the rapidly ad-
vancing development of reproductive medicine, genetic 
diagnosis and therapy and, if necessary, to take legislative 
action. The implications of PGD affect fundamental societal 
issues and values. This is why these implications should be 
addressed again and again in the public political debate.
being discussed. With regard to the question of the allowed 
number of eggs to be fertilised, a practice of fertilising more 
than the three eggs mentioned in the law has developed. In 
this respect, however, explicit clarification is called for.
An important change in the framework conditions would be 
to find an arrangement regarding reimbursement by the 
health insurance companies. Such an arrangement could in-
volve a change in the number of applications. However, this 
could only be realised by modifying social legislation. Fur-
thermore, the uncertainty and complexity of the approval 
procedure as well as the treatment itself represent limiting 
factors for PGD practice. Another important framework 
condition is the number of admissible indications. In many 
countries, the initially limited range of indications has been 
extended over time. In Germany, the PGD centres are cur-
rently discussing the assessment of late onset diseases such as 
Huntington’s disease and of genetic variants associated with 
a strongly increased probability of breast cancer. A particular 
question in this context are tests with regard to aneuploidies 
in the form of screenings (as a service for all IVF treatments). 
In response to demands for a general screening, it is argued 
that this would not be consistent with the objective of limiting 
the use of PGD. Moreover, the medical benefit with regard to 
improving the success of IVF treatments is questionable.
Last but not least, technological developments in the field 
of reproductive medicine and genetic diagnosis can funda-
mentally influence the practice of PGD. Next-generation se-
quencing (NGS) allows to examine the entire genome using 
sequencing techniques and is being used more and more of-
ten. In this way, it is no longer necessary to separate the test 
for monogenic disorders from that for chromosomal anom-
alies, since both can be carried out in one run only and in a 
relatively short time. However, these tests reveal more addi-
tional findings, the handling of which requires clarification.
Options for action
Detailed, up-to-date and publicly available data on the ap-
plication of PGD are required to provide monitoring pos-
sibilities for Parliament and civil society. In this context, 
however, consideration should be given to the possibility of 
